An observational study in Alzheimer Disease, Cognitive Impairment and Dementia, sponsored by Hospital del Mar Research Institute (IMIM). Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Hospital del Mar Research Institute (IMIM) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 26th largest by planned enrollment of the 39 observational ones that give a count, is one of 20 that started in 2024, is one of 39 observational ones, reaches primary completion later than 5 of the 79 other live ones, and was the 217th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
Hospital del Mar Research Institute (IMIM) is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Hospital del Mar Research Institute (IMIM) has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine whether the early adoption of blood-based biomarkers for Alzheimer's disease is associated with an impact on etiological diagnosis, patient's management, emotional impact, patient's preferences and cost-effectiveness in patients presenting with cognitive complaints in a Cognitive Disorders Unit from a public hospital.
The main questions it aims to answer are:
Participants will be asked to:
Researchers will compare the group in which blood biomarkers are delivered at 3 months with the group in which they are delivered at 9 months to assess whether early adoption of blood-based biomarkers is associated with an impact on etiological diagnosis, patient's management, emotional impact, patient's preferences and cost-effectiveness in a specialized memory unit.
Blood-based biomarkers that accurately detect Alzheimer's disease (AD) and neurodegeneration now offer a realistic, cost-effective and non-invasive assessment that will aid the diagnostic process in patients presenting with cognitive clinical manifestations. Plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) have shown high diagnostic accuracy to detect AD, while plasma Neurofilament light chain (NfL) indicates neuronal injury. Despite these promising results, there is still no clear real-word evidence of their clinical applications. Here, the PLASMAR project aims to determine whether blood-based biomarkers have an impact on the clinical management of patients presenting with cognitive complaints in a Cognitive Disorders Unit from a public hospital, which provides care to a heterogeneous population. The project is divided into two specific objectives. First, the investigators will determine, in a research cohort, which blood biomarker or biomarkers' combination have the highest accuracy to detect AD. Second, a prospective clinical cohort of consecutive patients coming to the memory unit will be recruited. The investigators will assess whether early adoption of blood-based biomarkers is associated with an impact on etiological diagnosis, patient's management, emotional impact, patient's preferences and cost-effectiveness in a specialized memory unit. Answering the question of whether blood-based biomarkers have a clinical impact in the real-world scenario of a memory unit, the PLASMAR project is crucial for the healthcare system and can guide the developing of guidelines and protocols on the use of blood-based biomarkers.
PLASMAR is prospective, unicentric, unblinded and randomized controlled study with blinded outcome ascertainment. Two hundred new patients will be consecutively recruited. All consecutive new patients who are visited for the first time to the outpatients' Memory Clinic at the Neurology Service (Hospital del Mar, Barcelona, Spain) will be considered for the study. Each patient will name a study partner to participate in this study, who will be considered for the study as well. In case the patient is diagnosed with dementia, a caregiver will be considered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The results of the blood-based biomarkers will be communicated to the managing neurologist at visit 1 (at 3 months from baseline visit).
Diagnostic Test: Early adoption of blood-based biomarkers for Alzheimer's disease
The results of the blood-based biomarkers will be communicated to the managing neurologist at visit 2 (at 9 months from baseline visit).
Diagnostic Test: Early adoption of blood-based biomarkers for Alzheimer's disease
A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
Etiological diagnosis
The proportion of patients for whom an etiologic diagnosis is reached with very high confidence (≥90%) in each group at 3 and 9 months.
Time frame: 9 months
Suspicion of neurodegenerative disease
The proportion of patients for whom a suspicion of neurodegenerative disease is reached as etiology with very high confidence (≥90%) in each group at 3 and 9 months.
Time frame: 9 months
Number of tests for etiological diagnosis
The number of tests necessary to reach an etiological diagnosis with very high confidence (≥90%) in each group at 3 and 9 months.
Time frame: 9 months
Number of tests for a suspicion of neurodegenerative disease
The number of tests to reach a suspicion of neurodegenerative disease as etiology with very high confidence (≥90%) in each group at 3 and 9 months.
Time frame: 9 months
Neurologist diagnoses over time
Changes in the neurologist's etiologic diagnosis in each group during the time of the study.
Time frame: 9 months
Neurologist confidence in the etiological diagnosis, which is is collected through the PLASMAR questionnaire at each visit.
Changes in the neurologist's estimate of the likelihood that the patient's symptoms are due to AD in each group during the time of the study.
Time frame: 9 months
Neurologist confidence in the suspicion of neurodegenerative disease, which is is collected through the PLASMAR questionnaire at each visit.
Changes in the neurologist's estimate of the likelihood that the patient's symptoms are due to a neurodegenerative disease as etiology in each group during the time of the study.
Time frame: 9 months
Number of patients whose clinical management in the Cognitive Disorders Unit changes
Changes in the prescription or withdrawal of disease-specific pharmacologic treatments (cholinesterase inhibitors, Memantine) and other pharmacologic or non-pharmacological interventions in addition to the number of patients who are discharged from the Cognitive Disorders Unit during the time of the study.
Time frame: 9 months
Emotional impact of blood-based biomarkers on patient and study partner/caregiver
Changes in Hospital Anxiety and Depression Scale (HADS; score: 0-42, with higher scores indicating higher anxiety or depression) and The Perceived Stress Scale (PSS; score: 0-40, with higher scores indicating higher perceived stress) during the time of the study.
Time frame: 9 months
Impact of blood-based biomarkers on patient's quality of life
Changes in the 5-level European Quality of Life-5 Dimensions scale (EQ-5D-5L; score: 5-25, with higher scores indicating worse severity index) during the time of the study.
Time frame: 9 months
Patient's tolerance to biomarkers tests and their preferences in how they want to be diagnosed
Tolerance score for each of the tests performed as part of clinical practice during the time of the study.
Time frame: 9 months
Relative cost savings from the Implementation of blood-based biomarkers in the Cognitive Disorders Unit.
The cost of the diagnostic work-up to achieve an etiologic diagnosis with very high confidence (≥90%) and the cost savings in resources (arising from pharmacological or non-pharmacological interventions, as well as discharges) will be combined to determine the relative cost of implementing blood-based biomarkers compared to their non-implementation.
Time frame: 9 months
Plan to share: No — There is not a plan to make IPD available.
Started Feb 2024 (actual). Primary completion is estimated for May 2025, 15 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 15 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital del Mar Research Institute (IMIM)